Bronchogen
AEDL TETRAPEPTIDE · KHAVINSON BIOREGULATOR · 4 AA · PRECLINICAL ONLY
also: AEDL · Ala-Glu-Asp-Leu · bronchial peptide bioregulator
Bronchogen is a synthetic tetrapeptide (AEDL) developed by Vladimir Khavinson's St Petersburg Institute of Bioregulation and Gerontology and marketed as a bronchopulmonary 'bioregulator'. Published work is limited to DNA-binding assays, organotypic culture, and a rat model of NO2-induced obstructive lung disease. Notably the rat study comes from a separate St Petersburg pulmonology institute with no Khavinson co-authors, but no human data of any kind was located.
// our evidence grade — unedited
There is no registered clinical trial and no identifiable published human study of AEDL; the evidence is a small set of cell-culture papers from Khavinson's St Petersburg group plus one rat COPD study from a separate Russian pulmonology institute, and the originating group's own 2014 review of clinical results does not list Bronchogen at all.
We grade this compound and we sell it. The grade is set against our published criteria before any stocking decision and is not adjusted because it is in the catalogue.
read the full evidence →// specification
| full name | Bronchogen (Ala-Glu-Asp-Leu, AEDL) |
| cas | 857267-12-0 |
| formula | C18H30N4O9 |
| molar mass | 446.5 g/mol |
| purity | ≥ 98% HPLC |
| form | lyophilised powder, sealed vial |
| storage | Lyophilised powder is stored desiccated at -20 °C and protected from light. Once reconstituted, laboratory practice is refrigeration at 2-8 °C for short-term use, or aliquoting and freezing to avoid repeated freeze-thaw cycles. Handling information only; this compound has no approved human use. |
| solubility | Short hydrophilic peptide, readily soluble in sterile or bacteriostatic water and in dilute aqueous buffer. Lot-specific solubility is stated on the certificate of analysis. |
| sequence | Ala-Glu-Asp-Leu (AEDL) |
// select size
crypto payment · research use only · not for human consumption
// others in Other